Publicaciones en colaboración con investigadores/as de Université Denis Diderot (4)

2018

  1. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204

2017

  1. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017

    European Journal of Cancer, Vol. 77, pp. 57-74

2016

  1. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB–IVA mycosis fungoides/Sézary syndrome

    British Journal of Dermatology, Vol. 175, Núm. 1, pp. 80-88

2013

  1. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial

    European Journal of Cancer, Vol. 49, Núm. 2, pp. 386-394